Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus

Basit Öğe Kaydı
dc.contributor.authorAtamer, Y.
dc.contributor.authorAtamer, A.
dc.contributor.authorCan, A. S.
dc.contributor.authorHekimoglu, A.
dc.contributor.authorIlhan, N.
dc.contributor.authorYenice, N.
dc.contributor.authorKocyigit, Y.
dc.date.accessioned2024-04-24T17:18:07Z
dc.date.available2024-04-24T17:18:07Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractHuman serum paraoxonase contributes to the anti-atherogenic effect of high-density lipoprotein cholesterol (HDL-C) and has been shown to protect both low-density lipoprotein cholesterol (LDL-C) and HDL-C against lipid peroxidation. We investigated the effects of rosiglitazone on paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus [50 patients (30 males, 20 females); mean +/- SD age: 58.7 +/- 9.2 years, body mass index: 28.2 +/- 4.1 kg/m(2)], in whom glucose control could not be achieved despite treatment with metformin, sulphonylurea, and/or insulin. The patients were given 4 mg/day rosiglitazone for 3 months in addition to their usual treatment. Serum paraoxonase activity, malondialdehyde, homocysteine, and lipid profile were measured at the time of initiation and at the end of therapy with rosiglitazone. After rosiglitazone therapy, serum levels of HDL-C, apolipoprotein A-1, and paraoxonase activity increased significantly (P<0.05) and malondialdehyde, homocysteine, lipoprotein(a), and glucose levels decreased significantly (P<0.05), but no significant changes in levels of total cholesterol and apolipoprotein B were observed. Triglyceride levels also increased significantly (P<0.05). Rosiglitazone treatment led to an improvement in glycemic control and to an increase in paraoxonase activity and HDL-C levels. Although rosiglitazone showed favorable effects on oxidant/antioxidant balance and lipid profile, further studies are needed to determine the effect of rosiglitazone on cardiovascular risk factors and cardiovascular morbidity and mortality.en_US
dc.identifier.doi10.1590/1414-431X20132818
dc.identifier.endpage532en_US
dc.identifier.issn0100-879X
dc.identifier.issn1414-431X
dc.identifier.issue6en_US
dc.identifier.pmid23802228
dc.identifier.scopus2-s2.0-84880391621
dc.identifier.scopusqualityQ1
dc.identifier.startpage528en_US
dc.identifier.urihttps://doi.org/10.1590/1414-431X20132818
dc.identifier.urihttps://hdl.handle.net/11468/18620
dc.identifier.volume46en_US
dc.identifier.wosWOS:000324573300007
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAssoc Bras Divulg Cientificaen_US
dc.relation.ispartofBrazilian Journal of Medical and Biological Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRosiglitazoneen_US
dc.subjectDiabetes Mellitus Type 2en_US
dc.subjectParaoxonaseen_US
dc.subjectLipoproteinsen_US
dc.subjectHomocysteineen_US
dc.subjectLipid Peroxidationen_US
dc.titleEffects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitusen_US
dc.titleEffects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu